Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS)

CNY 31.9

(0.73%)

Market Cap (In CNY)

27.85 Billion

Revenue (In CNY)

8.22 Billion

Net Income (In CNY)

986.7 Million

Avg. Volume

4.51 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
23.4-39.05
PE
-
EPS
-
Beta Value
0.777
ISIN
CNE000001808
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Ms. Lei Wang
Employee Count
-
Website
https://www.zhongxinp.com
Ipo Date
2001-06-06
Details
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and healthcare products primarily in the People's Republic of China. It operates in Chinese Medicine and Western Medicine segments. The company is also involved in the manufacture and sale of Chinese and western pharmaceutical and biological products; wholesale and retail sale of medicines, biochemical pharmaceutical products, and daily use products; and operation of hospitals. In addition, it provides logistics, stocks, equipment installation, and medicine processing services; medicine inspection and testing services; and pharmaceutical consultancy services. The company sells its medicinal products under its own brand to the wholesalers; and purchases medicinal products under other brands from distributors and sells these to other wholesalers. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited and changed its name to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in May 2022. Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited was incorporated in 1992 and is based in Tianjin, the People's Republic of China.

More Stocks